With over 30 years of experience we are adept at all aspects of cell culture.
Typical screens have required upwards of 1010 cells. We have developed methodologies to grow, sub-culture, harvest, cryopreserve and revive these quantities of cells from single batches, thus reducing screening variability, allowing cells to be used in an identical manner to other assay reagents, reviving and using what is required on a daily basis.
Bioassays & Screening
Aurelia Bioscience Ltd is a pre-clinical contract research company focusing on supplying biochemical and cell-based compound screening expertise to small to medium enterprise (SME) companies, universities, research institutes, charities and large pharmaceuticals companies.
Our vision is to be recognised by our clients, partners and peers as a centre of excellence for these activities. Underlying this is a desire to continue to contribute to the discovery of new therapeutic compounds for unmet medical need.
Our team has extensive experience of developing and screening compounds in biochemical assays for a range of targets including but not limited to proteases, kinases, and phosphodiesterase enzymes and protein:protein interaction.
Cell based assays are of key importance at a number of stages in the drug discovery process. Being able to examine the interaction between your target and compounds in a cellular context is of great advantage.
Our scientists have in-depth experience of label-free technology applied to cell-based assays gained over the past 6 years using Coring EPIC, Perkin Elmer EnSpire and SRU Bioscience Bind instruments.
Scientists at Aurelia have decades of experience between them working in real-world drug discovery projects utilising FLIPR, FMAT, EPIC label free and Envision-based assays in both biochemical and cell-based formats
A comprehensive service to drug discovery clients including assay development, reagent testing and scale-up, proof of technology concept and validation, phenotypic screening and consultancy.
The members of Aurelia Bioscience have been involved in the design and development of many drug discovery projects incorporating complex biology and implementing a suite of assays designed to identify “active” compounds and improve their biological properties.
Acting as an intermediary between instrument and reagent manufacturers and prospective clients we can provide an expert lab-based environment for the validation of new technologies.
Aurelia awarded Nottingham Technology (N'Tech) Grant Fund
The N’Tech grant programme funded by the Regional Growth Fund and delivered by Nottingham City Council is designed to support the development of business operating in the life science, digital content and clean technologies sectors.
“We are a niche bioscience research organisation that delivers a bespoke service to a range of global clients. The work we do is critical in the early stages of new medicines discovery. There is great optimism for growth in the life sciences sector. Nottingham and BioCity are taking a very active role in this.”
Kevin Hart – Managing Director and Founder
With our growing portfolio of clients and our diversification into new and innovative technologies and biological readouts, this grant will help us to exploit investment into capital and infrastructure to build upon our platform of biological readouts we offer to our clients.